{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T16:31:50Z","timestamp":1792773110927,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"DOI":"10.1007\/s11255-026-05210-4","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T07:02:22Z","timestamp":1779951742000},"page":"5061-5069","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Association between time in range and incident early diabetic kidney disease in patients with type 2 diabetes: a retrospective cohort study"],"prefix":"10.1007","volume":"58","author":[{"given":"Ling","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niuniu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,28]]},"reference":[{"issue":"4","key":"5210_CR1","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.mcna.2023.03.004","volume":"107","author":"S Gupta","year":"2023","unstructured":"Gupta S, Dominguez M, Golestaneh L (2023) Diabetic kidney disease: an update. Med Clin North Am 107(4):689\u2013705","journal-title":"Med Clin North Am"},{"issue":"6","key":"5210_CR2","doi-asserted-by":"publisher","DOI":"10.1177\/14791641211058856","volume":"18","author":"S Thipsawat","year":"2021","unstructured":"Thipsawat S (2021) Early detection of diabetic nephropathy in patient with type 2 diabetes mellitus: a review of the literature. Diabetes Vasc Dis Res 18(6):14791641211058856","journal-title":"Diabetes Vasc Dis Res"},{"issue":"8","key":"5210_CR3","volume":"15","author":"S Asghar","year":"2023","unstructured":"Asghar S, Asghar S, Mahmood T, Bukhari SMH, Mumtaz MH, Rasheed A (2023) Microalbuminuria as the tip of iceberg in type 2 diabetes mellitus: prevalence, risk factors, and associated diabetic complications. Cureus 15(8):e43190","journal-title":"Cureus"},{"issue":"12","key":"5210_CR4","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.2215\/CJN.11491116","volume":"12","author":"RZ Alicic","year":"2017","unstructured":"Alicic RZ, Rooney MT, Tuttle KR (2017) Diabetic kidney disease: challenges, progress, and possibilities. Clin J Am Soc Nephrol 12(12):2032\u20132045","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"5210_CR5","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/S2213-8587(13)70199-2","volume":"2","author":"E Selvin","year":"2014","unstructured":"Selvin E, Rawlings AM, Grams M, Klein R, Sharrett AR, Steffes M et al (2014) Fructosamine and glycated albumin for risk stratification and prediction of incident diabetes and microvascular complications: a prospective cohort analysis of the Atherosclerosis Risk in Communities (ARIC) study. Lancet Diabetes Endocrinol 2(4):279\u2013288","journal-title":"Lancet Diabetes Endocrinol"},{"key":"5210_CR6","doi-asserted-by":"crossref","unstructured":"Lazar S, Ionita I, Reurean-Pintilei D, Timar R, Luca SA, Timar B. To what extent is Hb(A1c) associated with glycemic variability in patients with type 1 diabetes? A retrospective, noninterventional study. Journal of clinical medicine. 2024;13(2)","DOI":"10.3390\/jcm13020450"},{"issue":"7","key":"5210_CR7","doi-asserted-by":"publisher","DOI":"10.4239\/wjd.v16.i7.107928","volume":"16","author":"UE Okpete","year":"2025","unstructured":"Okpete UE, Byeon H (2025) Limitations of glycated hemoglobin and emerging biomarkers for diabetes care after bariatric surgery. World J Diabetes 16(7):107928","journal-title":"World J Diabetes"},{"issue":"1","key":"5210_CR8","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.ecl.2019.10.010","volume":"49","author":"AL Carlson","year":"2020","unstructured":"Carlson AL, Criego AB, Martens TW, Bergenstal RM (2020) HbA(1c): the glucose management indicator, time in range, and standardization of continuous glucose monitoring reports in clinical practice. Endocrinol Metab Clin North Am 49(1):95\u2013107","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"4","key":"5210_CR9","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1177\/1932296818822496","volume":"13","author":"RW Beck","year":"2019","unstructured":"Beck RW, Bergenstal RM, Cheng P, Kollman C, Carlson AL, Johnson ML et al (2019) The relationships between time in range, hyperglycemia metrics, and HbA1c. J Diabetes Sci Technol 13(4):614\u2013626","journal-title":"J Diabetes Sci Technol"},{"issue":"5","key":"5210_CR10","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1097\/CM9.0000000000002582","volume":"136","author":"J Wan","year":"2023","unstructured":"Wan J, Lu J, Li C, Ma X, Zhou J (2023) Research progress in the application of time in range: more than a percentage. Chin Med J 136(5):522\u2013527","journal-title":"Chin Med J"},{"issue":"8","key":"5210_CR11","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.2337\/dci19-0028","volume":"42","author":"T Battelino","year":"2019","unstructured":"Battelino T, Danne T, Bergenstal RM, Amiel SA, Beck R, Biester T et al (2019) Clinical targets for continuous glucose monitoring data interpretation: recommendations from the International Consensus on Time in Range. Diabetes Care 42(8):1593\u20131603","journal-title":"Diabetes Care"},{"issue":"3","key":"5210_CR12","doi-asserted-by":"publisher","first-page":"345","DOI":"10.2337\/dci18-0040","volume":"42","author":"IB Hirsch","year":"2019","unstructured":"Hirsch IB, Sherr JL, Hood KK (2019) Connecting the dots: validation of time in range metrics with microvascular outcomes. Diabetes Care 42(3):345\u2013348","journal-title":"Diabetes Care"},{"issue":"3","key":"5210_CR13","doi-asserted-by":"publisher","first-page":"400","DOI":"10.2337\/dc18-1444","volume":"42","author":"RW Beck","year":"2019","unstructured":"Beck RW, Bergenstal RM, Riddlesworth TD, Kollman C, Li Z, Brown AS et al (2019) Validation of Time in Range as an Outcome Measure for Diabetes Clinical Trials. Diabetes Care 42(3):400\u2013405","journal-title":"Diabetes Care"},{"issue":"8","key":"5210_CR14","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1007\/s00125-024-06171-y","volume":"67","author":"J De Meulemeester","year":"2024","unstructured":"De Meulemeester J, Charleer S, Visser MM, De Block C, Mathieu C, Gillard P (2024) The association of chronic complications with time in tight range and time in range in people with type 1 diabetes: a retrospective cross-sectional real-world study. Diabetologia 67(8):1527\u20131535","journal-title":"Diabetologia"},{"issue":"Suppl 1","key":"5210_CR15","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.4103\/sja.SJA_543_18","volume":"13","author":"S Cuschieri","year":"2019","unstructured":"Cuschieri S (2019) The STROBE guidelines. Saudi J Anaesth 13(Suppl 1):S31\u2013S34","journal-title":"Saudi J Anaesth"},{"issue":"5","key":"5210_CR16","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1093\/jalm\/jfad047","volume":"8","author":"S Lu","year":"2023","unstructured":"Lu S, Robyak K, Zhu Y (2023) The CKD-EPI 2021 equation and other creatinine-based race-independent eGFR equations in chronic kidney disease diagnosis and staging. J Appl Lab Med 8(5):952\u2013961","journal-title":"J Appl Lab Med"},{"issue":"4s","key":"5210_CR17","first-page":"S117","volume":"105","author":"Kidney disease: improving global outcomes (KDIGO) CKD Work Group","year":"2024","unstructured":"Kidney disease: improving global outcomes (KDIGO) CKD Work Group (2024) KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int 105(4s):S117-s314","journal-title":"Kidney Int"},{"key":"5210_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2021-002573","author":"R Raj","year":"2022","unstructured":"Raj R, Mishra R, Jha N, Joshi V, Correa R, Kern PA (2022) Time in range, as measured by continuous glucose monitor, as a predictor of microvascular complications in type 2 diabetes: a systematic review. BMJ Open Diabetes Res Care. https:\/\/doi.org\/10.1136\/bmjdrc-2021-002573","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"3","key":"5210_CR19","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1089\/dia.2024.0404","volume":"27","author":"BP Kovatchev","year":"2025","unstructured":"Kovatchev BP, Lobo B, Fabris C, Ganji M, El Fathi A, Breton MD et al (2025) The virtual DCCT: adding continuous glucose monitoring to a landmark clinical trial for prediction of microvascular complications. Diabetes Technol Ther 27(3):209\u2013216","journal-title":"Diabetes Technol Ther"},{"issue":"10","key":"5210_CR20","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1089\/dia.2019.0499","volume":"22","author":"JH Yoo","year":"2020","unstructured":"Yoo JH, Choi MS, Ahn J, Park SW, Kim Y, Hur KY et al (2020) Association between continuous glucose monitoring-derived time in range, other core metrics, and albuminuria in type 2 diabetes. Diabetes Technol Ther 22(10):768\u2013776","journal-title":"Diabetes Technol Ther"},{"key":"5210_CR21","doi-asserted-by":"crossref","unstructured":"Mayeda L, Katz R, Ahmad I, Bansal N, Batacchi Z, Hirsch IB, et al. Glucose time in range and peripheral neuropathy in type 2 diabetes mellitus and chronic kidney disease. BMJ open diabetes research & care. 2020;8(1)","DOI":"10.1136\/bmjdrc-2019-000991"},{"key":"5210_CR22","doi-asserted-by":"crossref","unstructured":"Hoogeveen EK. The epidemiology of diabetic kidney disease. 2022;2(3):433-42","DOI":"10.3390\/kidneydial2030038"},{"issue":"2","key":"5210_CR23","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1053\/j.ackd.2017.10.011","volume":"25","author":"DN Koye","year":"2018","unstructured":"Koye DN, Magliano DJ, Nelson RG, Pavkov ME (2018) The global epidemiology of diabetes and kidney disease. Adv Chronic Kidney Dis 25(2):121\u2013132","journal-title":"Adv Chronic Kidney Dis"},{"issue":"6","key":"5210_CR24","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.2337\/db05-1620","volume":"55","author":"R Retnakaran","year":"2006","unstructured":"Retnakaran R, Cull CA, Thorne KI, Adler AI, Holman RR (2006) Risk factors for renal dysfunction in type 2 diabetes: U.K. prospective diabetes study 74. Diabetes 55(6):1832\u20131839","journal-title":"Diabetes"},{"issue":"8 Suppl","key":"5210_CR25","first-page":"S168","volume":"27","author":"LF Fried","year":"2021","unstructured":"Fried LF, Folkerts K, Smeta B, Bowrin KD, Mernagh P, Millier A et al (2021) Targeted literature review of the burden of illness in patients with chronic kidney disease and type 2 diabetes. Am J Manag Care 27(8 Suppl):S168\u2013S177","journal-title":"Am J Manag Care"},{"issue":"1","key":"5210_CR26","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.kint.2017.12.027","volume":"94","author":"HJL Heerspink","year":"2018","unstructured":"Heerspink HJL, Kosiborod M, Inzucchi SE, Cherney DZI (2018) Renoprotective effects of sodium-glucose cotransporter-2 inhibitors. Kidney Int 94(1):26\u201339","journal-title":"Kidney Int"},{"issue":"6","key":"5210_CR27","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/s41581-020-0256-y","volume":"16","author":"V Vallon","year":"2020","unstructured":"Vallon V, Thomson SC (2020) The tubular hypothesis of nephron filtration and diabetic kidney disease. Nat Rev Nephrol 16(6):317\u2013336","journal-title":"Nat Rev Nephrol"},{"issue":"24","key":"5210_CR28","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM et al (2019) Canagliflozin and renal outcomes in Type 2 diabetes and nephropathy. N Engl J Med 380(24):2295\u20132306","journal-title":"N Engl J Med"},{"issue":"15","key":"5210_CR29","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF et al (2020) Dapagliflozin in patients with chronic kidney disease. N Engl J Med 383(15):1436\u20131446","journal-title":"N Engl J Med"},{"issue":"12","key":"5210_CR30","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.2337\/dci22-0027","volume":"45","author":"IH de Boer","year":"2022","unstructured":"de Boer IH, Khunti K, Sadusky T, Tuttle KR, Neumiller JJ, Rhee CM et al (2022) Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care 45(12):3075\u20133090","journal-title":"Diabetes Care"},{"issue":"7","key":"5210_CR31","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1080\/1744666X.2025.2521086","volume":"21","author":"A Mima","year":"2025","unstructured":"Mima A, Nomura A, Yasuzawa T (2025) Update on the pathophysiology and treatment of diabetic kidney disease: a narrative review. Expert Rev Clin Immunol 21(7):921\u2013928","journal-title":"Expert Rev Clin Immunol"},{"issue":"8","key":"5210_CR32","doi-asserted-by":"publisher","first-page":"3488","DOI":"10.1007\/s12325-022-02223-0","volume":"39","author":"A Mima","year":"2022","unstructured":"Mima A (2022) A narrative review of diabetic kidney disease: previous and current evidence-based therapeutic approaches. Adv Ther 39(8):3488\u20133500","journal-title":"Adv Ther"},{"key":"5210_CR33","doi-asserted-by":"publisher","first-page":"15018","DOI":"10.1038\/nrdp.2015.18","volume":"1","author":"MC Thomas","year":"2015","unstructured":"Thomas MC, Brownlee M, Susztak K, Sharma K, Jandeleit-Dahm KA, Zoungas S et al (2015) Diabetic kidney disease. Nat Rev Dis Primers 1:15018","journal-title":"Nat Rev Dis Primers"},{"issue":"3","key":"5210_CR34","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/S2213-8587(18)30136-0","volume":"7","author":"A Ceriello","year":"2019","unstructured":"Ceriello A, Monnier L, Owens D (2019) Glycaemic variability in diabetes: clinical and therapeutic implications. Lancet Diabetes Endocrinol 7(3):221\u2013230","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"12","key":"5210_CR35","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.2337\/dc15-1188","volume":"38","author":"C Gorst","year":"2015","unstructured":"Gorst C, Kwok CS, Aslam S, Buchan I, Kontopantelis E, Myint PK et al (2015) Long-term glycemic variability and risk of adverse outcomes: a systematic review and meta-analysis. Diabetes Care 38(12):2354\u20132369","journal-title":"Diabetes Care"},{"issue":"1","key":"5210_CR36","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1007\/s00125-017-4423-z","volume":"61","author":"B Zinman","year":"2018","unstructured":"Zinman B, Marso SP, Poulter NR, Emerson SS, Pieber TR, Pratley RE et al (2018) Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2). Diabetologia 61(1):48\u201357","journal-title":"Diabetologia"},{"issue":"4","key":"5210_CR37","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1089\/dia.2017.0455","volume":"20","author":"TD Riddlesworth","year":"2018","unstructured":"Riddlesworth TD, Beck RW, Gal RL, Connor CG, Bergenstal RM, Lee S et al (2018) Optimal sampling duration for continuous glucose monitoring to determine long-term glycemic control. Diabetes Technol Ther 20(4):314\u2013316","journal-title":"Diabetes Technol Ther"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-026-05210-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-026-05210-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-026-05210-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T14:17:07Z","timestamp":1792765027000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-026-05210-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":37,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,11]]}},"alternative-id":["5210"],"URL":"https:\/\/doi.org\/10.1007\/s11255-026-05210-4","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,28]]},"assertion":[{"value":"5 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest related to this study.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the institutional ethics committee of the Affiliated Nantong Hospital of Shanghai University (NTLYLL2025049). The study was conducted in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The requirement for informed consent was waived due to the retrospective nature of the study.","order":3,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}}]}}